02 Feb NEJM: Effectiveness of Pediatric Meningococcal B Vaccine
MedicalResearch.com Interview with:
Manuel García Cenoz MD, PhDInstituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain CIBER Epidemiología y Salud Pública, Madrid
MedicalResearch.com: What is the background for this study?
Response: Neisseria meningitidis is a major cause of severe disease in infants and children. After the introduction of serogroup C vaccines, serogroup B meningococcus has become the main cause of invasive meningococcal disease in Europe. The multicomponent protein-based meningococcal B vaccine (4CMenB, Bexsero, GSK) was licensed in the European Union in 2013. Its authorization was based on immunogenicity studies. Although some countries have introduced the 4CMenB vaccine into the publicly-funded infant immunization programs, the low incidence of the disease has limited the conduct of post-commercialization studies of effectiveness.Meningococcal B vaccine began to be used in Spain in children in 2014, recommended by the Spanish Association of Pediatrics, and paid by their families as it was not publicly-funded. We have conducted a nationwide study including all confirmed cases of invasive meningococcal disease in Spain between October 2015 and September 2019 in children aged two months to five years.
MedicalResearch.com: What are the main findings?
- This study shows that children under 5 years of age who had received the complete vaccination regimen against meningococcus B had a 71% lower risk of suffering from invasive meningococcal disease by serogroup B than those who were not vaccinated.
- Children who had started vaccination but had not yet completed it, presented a 50% lower risk of the disease than those who were not vaccinated.
- Children under 5 years of age with a complete vaccination regimen had a 76% lower risk of invasive meningococcal disease from any type of meningococcus than those not vaccinated, since this vaccine also seems to have a preventive effect against meningococci other than B (as 4CMenB vaccine antigens are not unique to group B meningococcus)
MedicalResearch.com: What should readers take away from your report?
Response: The results of this study support the recent decision of the Spanish Ministry of Health to incorporate vaccination against meningococcus B in the publicly-funded childhood immunization schedule.
I have no conflicts of interest or other disclosures to report.
Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children
J. Castilla and Others
N Engl J Med 2023;388:427-438 February 1 2023
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website. Some links may be sponsored.